What does AI adoption actually look like inside Pfizer, a London specialty insurer, and Procter & Gamble? Three practitioners share real deployments — from AI-driven drug discovery and digital twin manufacturing to agentic underwriting and enterprise-wide upskilling — revealing where the technology delivers and where culture still stalls.

WHAT THIS PANEL COVERS

• Pfizer is embedding AI across the entire drug lifecycle — target discovery, clinical trial optimization, digital twin manufacturing, and personalized prescriber outreach — to compress a 10-15 year pipeline
• A London specialty insurer built agentic AI to extract submission data from unstructured documents and resolve entity matching, cutting underwriting time from days to hours with 90% feature coverage
• P&G tackles 'AI slop' head-on: flooding organizations with AI-generated content actually increases workload unless you first ask whether the use case genuinely adds business value
• Pfizer ties AI adoption to individual performance goals — from senior leadership down — creating measurable incentives rather than relying on voluntary uptake
• Trust in AI adoption is declining globally (Edelman 2025: only 23% positive in Germany), making culture change and transparency the real bottleneck, not the technology

PANELISTS

• Stephan Balzer — Keynote Speaker, Host & Moderator; Managing Director, red onion (Moderator)
• Sean Gundy — Head of Partnerships, Pfizer
• Brigitta Kudor — Founder & Principal Consultant, WeDoData
• Shaje Ganny — Director of Digital Transformation, Procter & Gamble; Co-Founder, Swiss AI Academy

unDavos is a community-driven summit running during WEF week in Davos, democratizing the conversation around global challenges.

🌐 undavos.com

Tags: AI adoption, enterprise AI, Pfizer, Procter & Gamble, AI use cases, agentic AI, digital twins, drug discovery, insurance AI, AI culture, upskilling, AI slop, trust in AI, Davos 2026, unDavos, REWIRE